Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post registration observational program for patients with locally recurrent or metastatic breast cancer who receive bevacizumab (Avastin) in combination with paclitaxel for the first-line treatment

Next Previous
X
Search
Trial Profile

Post registration observational program for patients with locally recurrent or metastatic breast cancer who receive bevacizumab (Avastin) in combination with paclitaxel for the first-line treatment

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms AVATAX
  • Sponsors Roche

    • Most Recent Events

    • 14 Sep 2021 Results (n=314; From January 2010 to February 2020) assessing safety and efficacy of the combination paclitaxel-bevacizumab in metastatic non-squamous non-small cell lung cancer as second-line therapy, presented at the 2021 World Conference on Lung Cancer.
    • 28 Nov 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Jul 2010 Planned end date changed from 1 Jun 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top